AbbVie Inc. (NYSE:ABBV) is one of the best stocks for the next decade. On December 12, Morgan Stanley raised the firm’s price ...

One key reason AbbVie has outperformed the market this year is that it has performed well financially. Through the first nine ...

AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

AbbVie Inc. (NYSE:ABBV) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026. On December 15, BofA lowered the ...

AbbVie's third-quarter earnings were disappointing, but the company raised its full-year guidance and increased the dividend.

In 2024, AbbVie’s presentation at the conference focused on its recent acquisitions of ImmunoGen and Cerevel. AbbVie paid ...

AbbVie and several other drugmakers are expected to announce on Friday agreements with the U.S. government to lower certain ...

Wondering if AbbVie is still a smart buy after its huge run, or if the value has already been squeezed out of the stock? Let us unpack what the current price really implies about its long term ...

The biopharmaceuticals giant and drugmaker want to create a leader across immunology, neuroscience, eye care, and other medical fields.

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $120.0 and $250.0 for AbbVie, spanning the last three months.

BofA lowered the firm’s price target on AbbVie (ABBV) to $233 from $248 and keeps a Neutral rating on the shares. The firm, which sees “a relatively clean setup” for growth at the high end of the peer ...

The stock price of AbbVie (NYSE: ABBV) reached its 52-week high of around $121 just last week before a recent sell-off in ABBV stock, especially after the U.S. FDA stated that all janus kinase ...